Date: 2017-03-27
Type of information: Nomination
Compound:
Company: Coherus Biosciences (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 27, 2017, Coherus BioSciences announced the appointment of Erik Wiberg as Executive Vice President of Corporate Development. Mr. Wiberg joins Coherus with more than 30 years of experience, including more than 18 years in various business development and corporate finance roles at biopharmaceutical companies, and 13 years in healthcare investment banking and equity research. In this position, Mr. Wiberg will be responsible for product licensing, corporate strategy, as well as M&A.
Financial terms:
Latest news:
Is general: Yes
